Use of an angiotensin ii receptor antagonist for the...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/415 (2006.01) A61K 31/4174 (2006.01) A61K 31/4178 (2006.01)

Patent

CA 2303217

The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotensin II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-il]methyl]-5- (hydroxymethyl)imidazole potassium salt.

Dans le but de préparer des médicaments servant à augmenter le taux de survie de patients transplantés, notamment les patients ayant subi une transplantation rénale et les patients ayant subi une transplantation cardiaque, cette invention propose d'utiliser, en quantité efficace sur le plan thérapeutique, un composé antagoniste du récepteur de l'angiotensine II, tel que les composés appartenant à la classe des imidazoles substituées représentées par la formule (I), et en particulier le potassium de losartan, sel potassium de 2-butyl-4-chloro-1-[(2'-tétrazol-5-yl)biphényle-4-il]méthyle]-5-(hydroxyméthyl)imidazole.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of an angiotensin ii receptor antagonist for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of an angiotensin ii receptor antagonist for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an angiotensin ii receptor antagonist for the... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1663808

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.